Danske Bank A S boosted its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 6.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 295,594 shares of the company’s stock after acquiring an additional 18,268 shares during the period. Danske Bank A S’s holdings in Zoetis were worth $20,641,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cassaday & Co Wealth Management LLC bought a new stake in Zoetis during the 1st quarter worth about $28,000. Wellington Grp LLC lifted its position in Zoetis by 6,675.0% during the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after purchasing an additional 267 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new position in Zoetis during the 2nd quarter valued at about $25,000. Dunhill Financial LLC boosted its stake in shares of Zoetis by 519.3% in the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock valued at $25,000 after purchasing an additional 296 shares during the last quarter. Finally, Dakota Community Bank & Trust NA boosted its stake in shares of Zoetis by 112.4% in the 1st quarter. Dakota Community Bank & Trust NA now owns 393 shares of the company’s stock valued at $46,000 after purchasing an additional 208 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.
Zoetis Trading Up 0.5%
NYSE:ZTS opened at $84.22 on Tuesday. Zoetis Inc. has a 1-year low of $68.77 and a 1-year high of $132.49. The business’s 50-day moving average price is $76.45 and its two-hundred day moving average price is $91.37. The company has a current ratio of 2.35, a quick ratio of 1.40 and a debt-to-equity ratio of 2.51. The firm has a market capitalization of $34.22 billion, a price-to-earnings ratio of 12.51, a PEG ratio of 1.20 and a beta of 0.67.
Zoetis (NYSE:ZTS – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.51 by $0.24. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.70 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.29 earnings per share for the current year.
Zoetis Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 annualized dividend and a yield of 2.5%. Zoetis’s dividend payout ratio (DPR) is presently 36.05%.
Analysts Set New Price Targets
Several brokerages have recently commented on ZTS. Morgan Stanley lowered their price target on shares of Zoetis from $85.00 to $82.00 and set an “overweight” rating for the company in a research report on Thursday, October 29th. Piper Sandler cut their price objective on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a report on Monday, August 10th. JPMorgan Chase & Co. reduced their price objective on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. BNP Paribas Exane lowered their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a report on Tuesday, August 11th. Finally, Jefferies Financial Group lifted their target price on shares of Zoetis from $83.00 to $85.00 in a report on Friday, November 6th. Eight equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $101.25.
Check Out Our Latest Stock Analysis on Zoetis
About Zoetis
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Further Reading
- Five stocks we like better than Zoetis
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
